Ajith Kumar, MD
Cardiovascular Disease · Newark, DENPI 1386611267
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $893 and has fallen 67.9% since, to $287 in 2025.
Across 228 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$482
- Novartis$434
- AstraZeneca$430
- Amgen$418
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$373
- Johnson & Johnson$286
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,21298%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $482 |
| Novartis | 21 | $434 |
| AstraZeneca | 27 | $430 |
| Amgen | 24 | $418 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $373 |
| Johnson & Johnson | 18 | $286 |
| Boehringer Ingelheim | 8 | $264 |
| Merck | 14 | $249 |
| Medtronic(2 entities) | 5 | $165 |
| Boston Scientific | 5 | $164 |
| Roche Diagnostics Corporation | 1 | $118 |
| GSK | 6 | $103 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Esperion Therapeutics, Inc. | 5 | $81 |
| Regeneron Healthcare Solutions, Inc. | 4 | $74 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $59 |
| Angiodynamics, Inc. | 1 | $53 |
| Tactile Systems Technology Inc | 2 | $36 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Lantheus Medical Imaging, Inc. | 2 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Atricure, Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $24 |
| Cook Medical LLC | 1 | $22 |
| Nuwellis, Inc. | 2 | $21 |
| Cardiovascular Systems Inc. | 2 | $19 |
| Cvrx, Inc. | 1 | $19 |
| Medicomp Inc | 1 | $19 |
| Cardinal Health 200 LLC | 1 | $18 |
| Bayer | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
| EKOS Corporation | 1 | $12 |
| Abbott | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRADAXA$125
- cobas 8000 Core Unit$118
- Resolute$102
How this compares
$4,288 in reported general payments places this provider in the 60th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 462 | $700,450 |
| Repatha SureclickEvolocumab | 249 | $313,736 |
| EntrestoSacubitril/Valsartan | 89 | $121,027 |
| XareltoRivaroxaban | 66 | $98,457 |
| JardianceEmpagliflozin | 74 | $89,283 |
| Praluent PenAlirocumab | 54 | $48,895 |
| NexlizetBempedoic Acid/Ezetimibe | 42 | $39,184 |
| FarxigaDapagliflozin Propanediol | 16 | $23,542 |
| Ezetimibe | 508 | $19,746 |
| Repatha SyringeEvolocumab | 18 | $13,850 |
| Rosuvastatin Calcium | 608 | $13,489 |
| Atorvastatin Calcium | 884 | $11,401 |
| Metoprolol Succinate | 413 | $7,391 |
| ClopidogrelClopidogrel Bisulfate | 254 | $3,965 |
| Ranolazine ErRanolazine | 42 | $3,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $482 | $700,450462 claims |
| NovartisEntresto | $434 | $121,02789 claims |
| Johnson & JohnsonXarelto | $286 | $98,45766 claims |
| Boehringer IngelheimJardiance | $264 | $89,28374 claims |
| Esperion Therapeutics, Inc.Nexlizet | $81 | $39,18442 claims |
| AstraZenecaFarxiga | $430 | $23,54216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.